Congress of the United States
Washington, DC 20515

May 23, 2017

Scott Gottlieb
Commissioner
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002

Dear Dr. Gottlieb:

We write today to express our strong disappointment with the final Guidance For Industry (GFI) issued by the Food and Drug Administration (FDA) on December 29, 2016, entitled “Prescription Requirement under 503A of the Food, Drug and Cosmetic Act”. The final GFI takes the position that state-licensed pharmacies cannot compound medications pursuant to state pharmacy laws for administration to patients in office or clinical settings (commonly referred to as “office-use compounding”).

Office-use compounding of medications is a common and often necessary medical practice that is authorized in some form by the vast majority of state pharmacy laws. Compounding for office-use done pursuant to state pharmacy laws does not make a pharmacy a drug manufacturer, and Congress never intended for the FDA to assert regulatory authority over the traditional practice of pharmacy, which has always been regulated at the state level.

The policies finalized in this GFI are contrary to the plain language of Section 503A as amended by the Drug Quality and Security Act (DQSA) and ignore clear, bipartisan, bicameral congressional intent expressed during passage of the bill. The FDA has unfortunately chosen to ignore broad and diverse stakeholder input, multiple congressional letters from both chambers, and clear directives in the House Report accompanying the FY2016 FDA appropriations legislation (House Report 114-205). More importantly, the FDA’s misinterpretation of the law and related enforcement actions against pharmacies are jeopardizing patients’ access to critical compounded medications. For these reasons, we respectfully request that the FDA immediately rescind this GFI and issue a proposed rule, with notice and stakeholder input as required by the Administrative Procedure Act, that is consistent with the DQSA and that allows for office-use compounding by state-licensed pharmacies where authorized by state pharmacy laws.

Particularly troubling is the fact that when finalizing this GFI from draft form, the FDA not only ignored congressional intent, stakeholder input, and clear directives in their FY16 funding legislation about office-use compounding, but also added new language not contained in the draft guidance that attempts to redefine the key and distinct terms “distribute” and “dispense”. It is astonishing that the agency would try to redefine these terms, which have commonly-accepted definitions both in existing law and in pharmacy practice, in a guidance document. This is a clear attempt by the FDA to assert unprecedented regulatory authority over the dispensing of medications and the traditional practice of pharmacy in a way that Congress never intended when passing the FDCA or its amendments in the DQSA. This regulatory overreach by the FDA and enforcement of the DQSA using guidance documents that don’t conform to the law is unacceptable and must stop.
In June of last year, sixty-one members of the House of Representatives, on a bipartisan basis, wrote to your predecessor Dr. Califf asking that the FDA finalize the draft GFI in a way that was consistent with the law and that protected both patient safety and access to critical medications compounded for office-use under state pharmacy laws. Unfortunately, the final GFI doubles-down on the FDA’s misinterpretation of the statute and will further exacerbate the patient access problem as more state-licensed and compliant pharmacies are forced to cease compounding office-use medications to the providers in their communities who rely on them for their patients’ needs.

We are hopeful that after rescinding this GFI, the incoming administration will re-evaluate the FDA’s policy on this subject and issue a proposed rule that provides a meaningful opportunity for stakeholder input and that adheres to the plain language and congressional intent behind the underlying statute. We look forward to working with you during this process.

Sincerely,

Chris Stewart  
Member of Congress

Earl L. ‘Buddy’ Carter  
Member of Congress

Mac Thornberry  
Member of Congress

Rob Bishop  
Member of Congress

Paul A. Gosar, D.D.S.  
Member of Congress

David P. Roe, M.D.  
Member of Congress

Pete Olson  
Member of Congress

Pete Sessions  
Member of Congress

Mia Love  
Member of Congress

Marshia Blackburn  
Member of Congress
Gus M. Bilirakis  
Member of Congress

A. Drew Ferguson IV, DMD  
Member of Congress

Rod Blum  
Member of Congress

Jaime Herrera Beutler  
Member of Congress

Billy Long  
Member of Congress

David Young  
Member of Congress

French Hill  
Member of Congress

Bill Flores  
Member of Congress

Henry Cuellar  
Member of Congress

Bob Goodlatte  
Member of Congress

Leonard Lance  
Member of Congress

Mike Gallagher  
Member of Congress

Darren Soto  
Member of Congress

Mimi Walters  
Member of Congress

Mario Diaz-Balart  
Member of Congress

Rodney Frelinghuysen  
Member of Congress
H. Morgan Griffith  
Member of Congress

Frank A. LoBiondo  
Member of Congress

Mark Pocan  
Member of Congress

John R. Carter  
Member of Congress

Collin C. Peterson  
Member of Congress

Ted Poe  
Member of Congress

Barbara Comstock  
Member of Congress

Jason Chaffetz  
Member of Congress

Doug Collins  
Member of Congress

Cathy McMorris Rodgers  
Member of Congress

Lou Barletta  
Member of Congress

Kevin Cramer  
Member of Congress

Walter B. Jones  
Member of Congress

C.A. Dutch Ruppersberger  
Member of Congress

Rick Crawford  
Member of Congress

Don Young  
Member of Congress
Andy Biggs
Member of Congress

Ted S. Yoho, D.V.M.
Member of Congress

Louie Gohmert
Member of Congress

Mark Walker
Member of Congress

Daniel M. Donovan, Jr.
Member of Congress

Rick W. Allen
Member of Congress

Carlos Curbelo
Member of Congress

Illeana Ros-Lehtinen
Member of Congress

David Joyce
Member of Congress

Robert Pittenger
Member of Congress

John Culberson
Member of Congress

Peter A. DeFazio
Member of Congress

Andy Barr
Member of Congress

David Rousse
Member of Congress

Vicente Gonzalez
Member of Congress

Mo Brooks
Member of Congress
John Rutherford  
Member of Congress

Austin Scott  
Member of Congress

Martha McSally  
Member of Congress

Randy Weber  
Member of Congress

Martha Roby  
Member of Congress

Barray Loudermilk  
Member of Congress

Roger Marshall  
Member of Congress